Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 67, Issue 5, 2008, Pages 620-624

  Gengenbacher, M ^a,b   Sebald, H J ^a,b   Villiger, P M ^a   Hofstetter, W ^b   Seitz, M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BONE METABOLISM; BONE TURNOVER; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG INHIBITION; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MORPHOMETRICS; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; AMINO ACIDS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE RESORPTION; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42449163799     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.076711     Document Type: Article

References (19)

1. Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik O, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004;164:543-55
2. Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 2004;50:265-76
3. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpa induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8
4. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not reguired for TNF-alpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 2004;19:207-13.
5. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005;208:19-29.
6. Balga R, Wetterwald A, Portenier J, Dolder S, Mueller C, Hofstetter W. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. Bone 2006;39:325-35.
7. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31.
8. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor KB, osteoprotegerin, and receptor activator of nuclear factor κB ligand. Arthritis Rheum 2004;50:3831-43.
9. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
10. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. AHRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
11. van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35:4-7.
12. Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, et al. Adaptation and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 2003;62:264-73.
13. Nocholson GC, Malakellis M, Collier FM, Cameron PU, Holloway WR, Gough TJ, et al. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kB ligand (RANKL). Clin Sci 2000;99:133-40.
14. Ramaswamy Y, Haynes DR, Berger G, Gildenhaar R, Lucas H, Holding C, et al. Bioceramics composition modulate resorption of human osteoclasts. J Mat Sci 2005;16: 1199-205.
15. Lafage-Proust MH, Boudignon B, Thomas T. Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 2003;70:109-18
16. Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 2003;42:123-34.
17. Yao Z, Li P, Zhang D, Schwarz EM, Keng P, Arbini A, et al. L. Tumor necrosis factor-alpha increases circulating osteoclast precursors numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 2006;281:11846-55.
18. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-90.
19. Lavigne P, Shi Q, Lajeunesse D, Dehnade F, Fernandes JC. Metabolic activity of osteoblasts retrieved from oseoarthritis patients after stimulation with mediators involved in periprosthetic loosening. Bone 2004;34:478-86.